

# **Product** Data Sheet

### P11149

Cat. No.:HY-105327CAS No.:164724-79-2Molecular Formula: $C_{27}H_{34}ClNO_4$ Molecular Weight:472.02

Target: Cholinesterase (ChE)
Pathway: Neuronal Signaling

**Storage:** 4°C, sealed storage, away from moisture

\* In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

### **SOLVENT & SOLUBILITY**

In Vitro

DMSO: 100 mg/mL (211.86 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.1186 mL	10.5928 mL	21.1855 mL
	5 mM	0.4237 mL	2.1186 mL	4.2371 mL
	10 mM	0.2119 mL	1.0593 mL	2.1186 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility:  $\ge$  5 mg/mL (10.59 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 5 mg/mL (10.59 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 5 mg/mL (10.59 mM); Clear solution

## **BIOLOGICAL ACTIVITY**

Description	P11149 is a competitive, BBB-penetarated weakly, orally active and selective inhibitor of AChE. P11149 exhibits an IC $_{50}$ of 1.3 $\mu$ M for rat BChE/AChE. P11149, a Galanthamine derivative, demonstrates central cholinergic activity, behavioral efficacy and safety. P11149 is used in the study for Alzheimer's disease <sup>[1]</sup> .
IC <sub>50</sub> & Target	AChE
In Vivo	P11149 is a GAL analog that is rapidly hydrolyzed in vivo to yield the potent AChE inhibitor, 6-DMG <sup>[1]</sup> . P11149 exhibits greater s.c. bioavailability than p.o. <sup>[1]</sup> . Oral P11149 in mice produces Sal, Lac and tremors at doses similar to those in rats, whereas 6-DMG, P1 1012 and GAL

produces Sal and Lac at doses lower than those in rats<sup>[1]</sup>. P11149 exhibits  $T_{1/2}(el)$  of 2.4 h and  $C_{max}$  of 585 ng/mL in rat plasma<sup>[1]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### **REFERENCES**

[1]. G M Bores, et al. Pharmacological evaluation of novel Alzheimer's disease therapeutics: acetylcholinesterase inhibitors related to galanthamine. J Pharmacol Exp Ther. 1996 May;277(2):728-38.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com